A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette
This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by y
| Condition(s) | Nicotine Dependence, Tobacco-Related Carcinoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by young adults requires effective and accessible treatments to support current users to quit. Research shows this group prefers and benefits from newer methods of treatment delivery such as digital interventions. ACT on Vaping is a digital therapeutic intended to deliver behavioral therapy to young adults who vape to motivate and support abstinence from all nicotine and tobacco products. The app contains sessions that promote awareness of cues that trigger tobacco use and teach |
| Who can participate | Inclusion Criteria: * Age 18-30 * Current weekly user of e-cigarette product(s) for the last 30 days * Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent) * Experience downloading and using one or more apps on their smartphone * Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app * Has access to text messaging * Has an email address * United States (US) resident, with a US mailing address * Willing to complete all study procedures * Comfortable reading and writing in English Exclusion Criteria: * Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during |
| Ages | 18 Years to 30 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Locations | Seattle, Washington, United States |
| Start date | 2026-06-15 |
| NCT ID | NCT06909500 |
| Official listing | https://clinicaltrials.gov/study/NCT06909500 |